APOLLOMICS INC. CLASS A ORDINARY SHARES
NASDAQ: APLM (Apollomics Inc.)
Last update: 6 hours ago18.49
1.77 (10.55%)
| Previous Close | 16.73 |
| Open | 16.33 |
| Volume | 18,656 |
| Avg. Volume (3M) | 45,668 |
| Market Cap | 39,630,504 |
| Price / Book | 7.37 |
| 52 Weeks Range |
| Operating Margin (TTM) | 1,007.39% |
| Diluted EPS (TTM) | -52.80 |
| Quarterly Revenue Growth (YOY) | 262.30% |
| Total Debt/Equity (MRQ) | 19.86% |
| Current Ratio (MRQ) | 1.39 |
| Operating Cash Flow (TTM) | -28.74 M |
| Levered Free Cash Flow (TTM) | -14.94 M |
| Return on Assets (TTM) | -75.07% |
| Return on Equity (TTM) | -233.67% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Apollomics Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 0.25 |
|
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 36.50% |
| % Held by Institutions | 0.22% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Harbour Investments, Inc. | 30 Sep 2025 | 50 |
| Sbi Securities Co., Ltd. | 30 Sep 2025 | 19 |
| Date | Type | Details |
|---|---|---|
| 22 Dec 2025 | Announcement | Apollomics Reports First Half 2025 Financial Results |
| 19 Nov 2025 | Announcement | Apollomics Announces Settlement of Cayman Litigation |
| 17 Nov 2025 | Announcement | Apollomics Announces Changes to its Board of Directors and Composition of Committees |
| 15 Oct 2025 | Announcement | Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation |
| 14 Oct 2025 | Announcement | Nasdaq Resumes Trading in Apollomics Inc. |
| 13 Oct 2025 | Announcement | Apollomics, Inc. Company Operational Continuity Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |